Aimoxi Releases 2025 Report, Industry Adjustment Period Demonstrates Operational Resilience, Internationalization Strategy Achieves Substantial Breakthrough

The Chinese medical aesthetics market in 2025 is entering a new round of reshuffling and reshaping. On one hand, as the market continues to expand and regulations tighten, the supply of compliant products increases, offering consumers more choices; on the other hand, the crowded track leads to intensified homogenized competition, with various competitive tactics emerging constantly. Meanwhile, under macroeconomic pressure, consumers are becoming more selective and cautious, shifting the industry from past extensive expansion to more refined and precise development. In this new cycle, the industry is bidding farewell to growth driven solely by marketing expansion and is instead entering a “marathon” focused on technology, safety, and brand depth. There is a growing consensus in the medical aesthetics industry: only through technology-driven innovation and deepening product strength can a true moat be built, enabling long-term competitive advantage.

As a leading enterprise in China’s medical aesthetics industry, Aimeike Technology Development Co., Ltd. (hereinafter referred to as “Aimeike” or “the Company”) released its 2025 annual report on the evening of March 19. The report shows that, despite short-term performance pressures in a complex market environment, the company proactively adjusted and responded, demonstrating strong resilience in core product profitability, R&D innovation investment, and international expansion, thus accumulating momentum for sustainable long-term development.

Short-term performance pressures do not alter profitability fundamentals

During the reporting period, influenced by macroeconomic fluctuations, intensified industry competition, and cautious consumer willingness, the company achieved operating revenue of 2,452.62 million yuan and net profit of 1,291.02 million yuan. The company’s total assets at the end of the period were 8,908.05 million yuan, an increase of 567.56 million yuan from the beginning of the period. Meanwhile, the company’s overall gross profit margin was 92.70%, maintaining a high level above 90% despite increased industry competition, fully reflecting the brand premium and cost control advantages of its products.

Notably, during the period, the company’s newly launched lyophilized powder injection products achieved revenue of 208.08 million yuan in just seven months, demonstrating strong market explosive power. As an important step in the company’s internationalization strategy, the rapid volume growth of lyophilized powder injections not only validated their acceptance in end markets but also further expanded the company’s growth boundaries. As consumer awareness of niche categories continues to rise, this product is expected to open new growth space for the company and become a key support for future performance.

Enhancing brand building and establishing an academically centered operational model

In terms of brand development, Aimeike is gradually moving away from traditional one-way output models to build a content-driven, doctor-centric operational system. During the reporting period, the company relied on the “Quanxuan Classroom” doctor training platform to continuously strengthen online and offline academic promotion, inviting experts to co-develop the project “On Facial Style Aesthetic Models,” and establishing a personalized aesthetic evaluation and treatment system. These initiatives not only empower medical aesthetics practitioners with professional knowledge but also promote the development of industry aesthetic standards. By the end of 2025, “Quanxuan Classroom” had served over 30,000 certified doctors, accumulating an academic resource library with more than 2,000 items.

Meanwhile, Aimeike has accelerated its presence on new media platforms. The company launched the “Quanxuan New Media” platform targeting doctors, institutional managers, and industry operators, collaborating with high-quality content creators and professional运营机构 to focus on brand management and value dissemination around core products. By offering courses on doctor IP branding, online customer acquisition, and refined operations, Aimeike aims to deeply integrate content creation, doctor value, and institutional efficiency, further strengthening the brand penetration of its end services.

Additionally, the company has made progress in digital infrastructure. Over the past year, Aimeike continued to build and improve information systems, promote data connectivity, and implement digital and AI applications across multiple business segments. By establishing three major data centers—customer, user, and content—the company completed data asset integration and refined operations, gradually forming a closed loop of “data integration—intelligent analysis—business empowerment.” This system is becoming an important support for improving management efficiency, customer service capabilities, and risk control.

Conclusion

2025 marks a year when the medical aesthetics industry shifts from product competition to ecosystem competition, transitioning from incremental market competition to stock market competition, and a key year for Aimeike’s strategic transformation. Facing a deep industry adjustment cycle, the company will continue to adhere to innovation-driven development, deepen its domestic market presence, expand overseas, and solidify core competitive advantages. Through steady operations and sustainable growth, it aims to reward investors and consumers’ trust and support. Looking ahead, Aimeike will continue to uphold the mission of “Using technology to enhance beauty,” focusing on strategic layout across products, technology, services, and ecosystems in the medical aesthetics industry, and continuously strengthening its core competitiveness.

Disclaimer: This content is from partner media. The publication of this article is for the purpose of conveying more information. The content is for reference only and does not constitute investment advice.